City Hospital

Hospital Management

Thynkwyse Technologies

A city hospital is a healthcare facility located in an urban area, often within a city or metropolitan region.

Mobile Number

+44 7397080961

Date of Birth



128 City Road, London, United Kingdom,

QR Code

Our Services

Medical Services

Medical Services

City hospitals offer a comprehensive range of medical services, including emergency care, surgery, diagnostic testing, primary care, and specialized medical treatments. They may have departments for cardiology, orthopedics, obstetrics, pediatrics.

Emergency Care

Emergency Care

City hospitals frequently have well-equipped emergency departments that operate 24/7 to provide immediate medical attention to individuals with acute illnesses, injuries, or life-threatening conditions.

Medical Staff

Medical Staff

City hospitals employ a diverse medical staff, including physicians, nurses, surgeons, specialists, and other healthcare professionals. They work together to provide a broad spectrum of medical care.

Community Healt

Community Healt

City hospitals often engage in community outreach and public health programs to address the health needs of the local population, promote wellness, and prevent disease.



The oncology team at City Hospital has been instrumental in my cancer journey. Their dedication to my well-being, the advanced treatments, and the emotional support they provide have been crucial in my fight against cancer

My father has been a resident at City Hospital for over a year now, and I'm continually impressed by the level of care and attention he receives. The staff is not just professional, but also genuinely caring


Computational Analysis of Drug Therapy Options for

Abstract Glioblastoma (GBM) is the most common primary brain tumor in the US and European countries and also the deadliest. Glioblastoma cells exhibit a different gene expression profile from normal cells. There are 601 known mutations in GBM tumors. The aim of this study was to identify the most important proteins in the glioblastoma pathway that lack drug treatments. A total of 15 proteins were identified as pathway starters or driver proteins and 52 proteins were identified as passenger proteins using 3 databases. Protein-protein interaction maps and heatmaps were created and proteins were ranked based on the number of connections each protein exhibited. The top 9 proteins were identified that are important in the GBM pathway. Then a protein-drug interaction map and heat map were created to find influential disease-causing proteins that currently lack drug treatments. Through this method, TERT, MDM2, and RB1 were found to be important proteins that lacked drug treatments. Drug development is needed to target these genes and a multiple target approach is needed since more than one pathway is involved in all GBMs. This could lead to new therapeutic options for glioblastoma. Introduction Glioblastoma Multiforme (GBM) is the most malignant form of brain tumor with a median survival of 15 months. 1 The annual incidence of GBM is 3.19 per 100,000 people in the USA.2 Glioblastoma is caused by over-expression of oncogenes, inactivation of tumor-suppressor genes, and dysregulation of signaling proteins. A number of abnormalities in protein pathways lead to the development and growth of this tumor. There are 601 known mutations in GBM tumors, some of which regulate the key steps that contribute to tumor development and growth.3 For this reason, I used a computational method to find the most important proteins in GBM for future drug research. The current treatment of GBM includes surgical resection of the tumor, followed by radiation and chemotherapy. Surgical treatment of cancerous tumors usually involves the removal of some normal tissue surrounding the tumor, in order to ensure that there are no microscopic remnants of the tumor. This helps in preventing the recurrence of these tumors. GBM is extremely hard to remove completely by surgery because of its ill-defined boundaries and location. An attempt to remove normal brain tissue surrounding the tumor can lead to serious neurological sequelae. Therefore, radiation and chemotherapy are given to kill the remaining tumor tissue. Radiation has similar limitations as surgery because it can destroy normal brain tissue also. Chemotherapy, given in the form of drugs, targets various proteins involved in the tumor development and growth pathway in order to prevent a recurrence. The five-year survival rate with current treatment regimens is only 4-5% and the median survival is 15 months. 1 There is an unmet and urgent clinical need for new drug development in this area. Objective My objective is to identify the most influential disease-causing proteins that are overexpressed or dysregulated in the tumorigenesis pathways involved in the initiation and development of glioblastoma through protein-protein interaction maps and to find proteins that lack drug treatments through protein-drug interaction maps. Methods Creating a set of proteins whose protein-protein interactions should be examined Three databases were studied to identify driver genes or pathway starters in glioblastoma. A starter or driver protein is the main protein that initiates a cellular pathway. A passenger protein is a protein that plays a minor role somewhere along the cellular pathway but is not essential to it. These databases were KEGG (Kyoto Encyclopedia of Genes and Genomes), COSMIC (Catalogue Of Somatic Mutations In Cancer), and TCGA (The Cancer Genome Atlas)4,5,6 A total of 15 pathway starter proteins were recorded using these databases. These 15 proteins are EGFR, PDGFRA, PTEN, PIK3CA, PIK3R1, H3F3A, TERT, RB1, MDM2, CHEK2, CDK4, CDKN2A, TP53, NF1, and IDH1. From these sources, 52 other proteins were also identified as important in glioblastoma pathways but were not pathway starters. These are the so-called passenger proteins.


My sincere and heartfelt thanks to Dr. Ravi Patel for giving me the opportunity to perform research at the Falk Cardiovascular Center at Stanford University. I thank him for providing insight and direction to my research interests. I am grateful to Daryl Waggott, my primary mentor, who has been a constant pillar of support throughout this incredible experience. Daryl was always eager and readily available to provide answers to the numerous questions that I had with a smile. Thank you so much for putting up with me. Additional thanks to Terra Coakley for her patience and support. I couldn’t have done this without her help and support. I am honored and immensely thankful that the Ashley Lab accommodated a high school junior amidst their overwhelming busy schedules. I am grateful to have been given the chance to perform research in such a world-class institution amongst some of the most well renowned and pioneering scientists in their fields. Thanks to my computer science teacher, Mr. Christopher Kuszmaul, for encouraging my passion to take wings. He has always supported my strong belief that computer science has the power to provide simple solutions to complex global problems. Last but not least, thanks to my wonderful parents and brother for their support and unconditional love. Abstract The purpose of this research is to identify potential new biomarkers for the diagnosis of heart failure. Heart failure, a chronic condition in which the heart is unable to supply sufficient oxygen for the needs of the tissues, is one of the leading causes of mortality in the United States. Finding an informative biomarker is imperative. Though a small number of biomarkers for the diagnosis of heart failure exist, these lack discriminatory power and are not appropriate for all patient populations. Biomarkers are considered superior to other methods of diagnosis because of their objectivity and ability to enable non-invasive diagnosis. This study created a generalizable computational genetics framework that combined publicly available RNA-Seq and microarray datasets pertaining to heart failure. The framework includes pre-processing, statistical analysis steps and features a prioritization algorithm. The R-Programming environment was used. Extensive quality control and validity checks were performed as well as a meta-analysis of the data. The study yielded thirty-eight potential gene candidates, the protein products of which we hypothesize could serve as new biomarkers of heart failure. Of the thirty-eight gene candidates, FHOD3 and DSG2 are most notable due to their secreted nature, known ties to heart conditions, and their high expression values in the plasma of heart failure patients. The findings of this study have several implications as they impact the diagnosis of heart failure for patients with genetic susceptibility to the disease. Better biomarkers, especially those that can help predict treatment options, are the future of this field. These candidates lay the foundation for moving this research forward. Introduction Heart Failure (HF) is a chronic condition in which the heart is unable to supply sufficient oxygen for the normal functions of body tissues. Its commonality and high mortality rate make it a major health problem not only in the United States but also worldwide. As of late, an estimated 23 million people worldwide are living with HF (Gaggin & Januzzi, 2013). Finding non-invasive means for the accurate diagnosis, prognosis and guided therapy of HF has become imperative. Biomarkers are non-invasive objective tools that are indicative of a biological state or condition. Ideal biomarkers are safe, easy to measure, and are consistent across sex, ethnic groups, and other stratifying factors. In the case of HF, biomarkers have impacted the way that the illness is diagnosed and monitored (Gaggin & Januzzi, 2013). Since natriuretic peptides (NPs) were discovered in 1985, they have been established as the best biomarkers of HF (Loncar et al., 2014). Their prognostic abilities and therapeutic values are well established. Although NPS is considered to be the “gold standard” biomarkers of HF, they face several limitations and setbacks. Factors known to influence the clinical interpretation of NPS include age, obesity, atrial arrhythmias, renal failure, and structural heart disease beyond the clinical diagnosis of HF (Loncar et al., 2014). In 2007, The National Academy of Clinical Biochemistry (NACB) set comparable goals in a consensus document that states that a biomarker in HF ideally enables clinicians to: “identify possible underlying (and potentially reversible) causes of HF; confirm the presence or absence of the HF syndrome; and estimate the severity of HF and the risk of disease progression” (Tang et al., 2007). Remarkably, NPS failed to meet the standards set by the NACB. Additionally, no other available biomarkers for HF have satisfied these guidelines. The lack of a sufficient and capable biomarker for HF furthers the need for the discovery of new biomarkers that has discriminatory powers under a variety of demographic and clinical settings. We hypothesize that it is possible to identify candidate biomarkers of heart failure by combining multiple datasets in an analytically structured framework. Materials and Methods This study combines three microarray datasets of studies pertaining to HF with one RNA-Seq HF dataset through the use of an analytically structured framework. It jointly pre-processes and analyzes the data to produce a list of possible biomarkers for heart failure. A joint analysis of datasets from RNA-Seq and Microarray data has proved to be difficult in the past due to the vastly different technical modalities employed by the platforms. This study was able to overcome the barrier of combining RNA-Seq datasets with Microarray datasets, thus maximizing the potential of all the candidate biomarkers produced. The R-Programming language (R Development Core Team, 2008) and several Bioconductor packages were used to perform all statistical analysis steps in the framework created by the study. The R-Programming environment was chosen due to its ease in enabling statistical computation and graphics. It is useful for a large number of statistical procedures. Figure 1 gives a breakdown of the study design and framework created by the study.

Business Hours

Monday 12:00 AM - 12:15 PM
Tuesday 12:00 AM - 12:15 PM
Wednesday 12:00 AM - 12:15 PM
Thursday 12:00 AM - 12:15 PM
Friday 12:00 AM - 12:15 PM
Saturday 12:00 AM - 12:15 PM
Sunday 12:00 AM - 12:15 PM

Make an Appointment


Made By Cardz - vCard Builder